The Part D Peak: Big Pharma's Blowout Quarter
This article was originally published in RPM Report
Executive Summary
While many people were watching the Senate grapple with drug price negotiation authority for CMS, Big Pharma blew past Wall Street's expectations with big first quarter gains. One year into the program, Medicare is definitely paying off. But will the party last?
You may also be interested in...
The Latest Furor Over Trump’s Drug Pricing Plan
Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?